Published in

Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia, Acta Cirurgica Brasileira, suppl 1(28), p. 83-87, 2013

DOI: 10.1590/s0102-86502013001300016

Links

Tools

Export citation

Search in Google Scholar

Does rosmarinic acid underestimate as an experimental cardiovascular drug?

Journal article published in 2013 by Albuquerque,Agnes Afrodite Sumarelli, Tales Rubens de Nadai ORCID, Luciana Garros Ferreira, Ferreira,Luciana Garros, Celotto,Andrea Carla, Andrea Carla Celotto, Verena Kise Capellini, Capellini,Verena Kise, Agnes Afrodite Sumarelli Albuquerque, Nadai,Tales Rubens De, Tales Rubens de Nadai, Carvalho,Marco Tulio Menezes De, Marco Tulio Menezes de Carvalho, Marco Tulio Menezes de Carvalho, Evora,Paulo Roberto Barbosa and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

PURPOSE: The rationale of the present review is to analize the activity of Rosmarinus officinalis in the the cardiovascular system METHODS: A MEDLINE database search (from January 1970 to December 2011) using only rosmarinic acid as searched term. RESULTS: The references search revealed 509 references about rosmarinic acid in 40 years (the first reference is from 1970). There is a powerful prevalence of antioxidant and cancer studies. Other diseases are few cited, as inflammation, brain (Alzheimer and Parkinson disease) and, memory; allergy; diabetes; atherosclerosis, and; hypertension. It is necessary to consider the complete absence of studies on coronary artery disease, myocardial ischemia, heart failure or ischemia/reperfusion injury. CONCLUSION: Rosmarinic acid is underestimated as an experimental cardiovascular drug and deserves more attention.